$LBRX

Biotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.

LB Pharmaceuticals Inc (Nasdaq: LBRX) said it entered a securities purchase agreement for a private placement selling 3,577,560 shares of common stock and pre-funded warrants for up to 715,513 shares. Price was $34.94 per share and $34.9399 per pre-funded warrant. Gross proceeds are expected at about $150 million, before expenses, closing around July 30, 2026. Net proceeds will fund LB-102 pipeline expansion and working capital.

LB PHARMACEUTICALS INC (LBRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 d156920dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is dated as of July 28, 2026, by and among LB Pharmaceuticals Inc, a Delaware corporation (the “ Company ”), and each of the entities lis

Biotech shares hit 52-week highs on July 28, 2026. Incyte (INCY) rose over 9% to $132.58 after Q2 revenue of $1.67B, up 38% year over year, and raised full-year net sales guidance to $5.13B-$5.26B. Pulse Biosciences (PLSE) gained over 8% to $36.29. Other climbers included Shoulder Innovations (SI), Bioventus (BVS), and LB Pharmaceuticals (LBRX).

Biotech stocks hit 52-week highs on July 22, 2026. Advanced Biomed (ADVB) jumped over 73% to $18.73. BioLife Solutions (BLFS) rose over 6% to $31.49 after Repligen (RGEN) agreed to acquire it for about $1.5B. Forte Biosciences (FBRX) rose over 11% to $56.84. Silence Therapeutics (SLN) rose over 9% to $11.90. LB Pharmaceuticals (LBRX) rose over 10% to $36.59.

A healthcare sector roundup highlights biotech stock moves. Zhongchao (ZCMD) rose about 192% after a 1-for-3 reverse split for Nasdaq compliance. Lakewood-Amedex (LABT) gained about 83% on positive Nu-3 Phase 2-ready updates. Arrowhead (ARWR) jumped about 19% after SHASTA-3/4 topline results for Plozasiran. Other gainers included MSLE, DRIO, and LBRX.

LB Pharmaceuticals Inc (Nasdaq: LBRX) said it granted an inducement equity award to new Senior VP Clinical Operations Christopher Zergebel on July 10, 2026 under Nasdaq Rule 5635(c)(4). The award is a 10-year option for 75,000 shares at a $32.95 exercise price, vesting over 4 years. The company also reiterated LB-102 Phase 2 and ongoing Phase 3 plans.

LB PHARMACEUTICALS INC (LBRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 d221514dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 June 8, 2026 Anna Eramo, M.D. Dear Anna: This letter sets forth the substance of the separation agreement (the “ Agreement ”), by and between LB Pharmaceuticals Inc (the “ Company ”) and you, which confirms our mutual agree

LB PHARMACEUTICALS INC (LBRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001691082 0001691082 2026-06-03 2026-06-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2

LB Pharmaceuticals (NASDAQ: LBRX) announced its Q1 2026 financial results, reporting a widened net loss of $19.1 million due to increased R&D and G&A expenses. The company has a strong cash position of $365.6 million, projected to fund operations into Q2 2029, supporting the advancement of its lead drug LB-102 through multiple clinical trials for neuropsychiatric indications. Key trials include the pivotal Phase 3 NOVA-2 for acute schizophrenia, Phase 2 ILLUMINATE-1 for bipolar depression, and a planned Phase 2 for adjunctive major depressive disorder, with topline data expected between late 2027 and early 2029.